Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor agonists are an exciting possibility for cancer treatment due to their ability to induce apoptosis in cancer cells while having little effect on normal cells. This evidence concerns the gene TNF and cancer.